share_log

Benchmark Upgrades Emergent BioSolutions to Buy, Announces $22 Price Target

Benchmark Upgrades Emergent BioSolutions to Buy, Announces $22 Price Target

Benchmark 将Emergent BioSolutions上调至买入,宣布
Benzinga ·  2023/04/10 06:57

Benchmark analyst Robert Wasserman upgrades Emergent BioSolutions (NYSE:EBS) from Hold to Buy and announces $22 price target.

基准分析师罗伯特·瓦瑟曼将Emergent BioSolutions(纽约证券交易所代码:EBS)从持有上调至买入,并宣布了22美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发